Document is current

Article History

Received: 13 December 2025

Revised: 20 February 2026

Accepted: 3 March 2026

First Online: 7 April 2026

Declarations

:

: The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Fundación Jimenez Díaz (Madrid, Spain; code No. 06/24).

: The study was conducted using anonymized databases. Therefore, informed consent was not required and as such was approved by the Ethics Committee.

: Federico Rojo reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: Menarini-Steamline, MSD, AstraZeneca, Incyte, Pfizer, Roche, AbbVie, Merck, Novartis, Lilly, Astellas, GSK, Amgen, Janssen, Agilent, Sophia Genetics. Research Funding: Menarini-Steamline, AstraZeneca, AbbVie, Astellas, Pfizer, and Roche. Conxi Lazaro has received speaker honorarium from AstraZeneca, Pfizer, and Illumina. Ihab Abdulkader-Nallib has been advisory board member for Pfizer, MSD, and AstraZeneca; has received speaker honorarium from Roche Diagnostics, Lilly, Pfizer, AstraZeneca, Takeda, Janssen, and Agilent; has received research grants to institution from AstraZeneca, BMS, and Pfizer; and has received travel grants from Roche Diagnostics, Lilly, Pfizer, AstraZeneca, Takeda, Janssen, and Agilent. Carlos Camps-Herrero declares no conflict of interest related to the topic of the article. Esther Roselló has received research grants to institution from AstraZeneca for HRD analysis. Miguel de la Hoya has received advisory honorarium from AstraZeneca Pharmaceutical Spain, S.A. Nerea Carvajal reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: Menarini-Steamline, MSD, AstraZeneca, Incyte, and Pfizer. Maribel González-Acosta has received speaker honorarium from AstraZeneca. Tamara Pereira-Ares reports no conflict of interest. Cristina Caballero reports no conflict of interest. Alicia Gómez-Sanz reports no conflict of interest. Sandra Pérez-Buira: payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: Menarini-Steamline. Maria del Rosario Taco-Sanchez reports no conflict of interest. Raquel Pérez-Becerra reports no conflict of interest. Maria Colomar-Roig reports no conflict of interest. Victor Lorca reports no conflict of interest. Sandra Zazo reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: Menarini-Steamline, MSD, and AstraZeneca. Mar Varela reports no conflict of interest. María Sánchez-Ares has received speaker honorarium from Roche Diagnostics, Lilly, and Agilent; and has received travel grants from Roche Diagnostics, AstraZeneca, Agilent, MSD, Pfizer, and Qiagen. Eloisa Jantus-Lewintre has received research grants to institution from AstraZeneca. Pedro Pérez-Segura has received research grants to IdISSC from AstraZeneca Pharmaceutical Spain, S.A. Sergi Villatoro reports no conflict of interest. Lara Navarro reports no conflict of interest. Nuria Santonja-Lopez reports no conflict of interest. Susana Torres-Martínez reports no conflict of interest. Xavier Matias-Guiu reports lectures and associated travel expenses from Roche Farma, Qiagen, Ferrer Internacional, Novartis, Menarini, Biocartis, Agilent-Dako, Leyca, Reig Jofre, Sysmex, MSD, AstraZeneca, BMS, GSK, Clovis, Eisai, and 3DHISTECH; and has been advisory boards member for AstraZeneca, Lilly, Amgen, GSK, Janssen, Illumina, MiMARK Diagnostics, MSD, Daiichi Sankyo, Inc., AbbVie, CellsIA, and Dreampath.